What are the indications, recommended dosing, and contraindications for norepinephrine (noradrenaline) infusion in patients with persistent hypotension?

Norepinephrine: Uses, Dosage, and Contraindications

Norepinephrine is the first-choice vasopressor for treating fluid-refractory hypotension in distributive shock (particularly septic shock), with a target MAP of 65 mmHg, and should be avoided as monotherapy in hypovolemic shock until volume resuscitation is adequate. 1

Primary Indications

Distributive Shock (First-Line)

• Septic shock: Norepinephrine is the gold standard first-line vasopressor after adequate fluid resuscitation 2, 1
• Target MAP of 65 mmHg initially, though individualized targets may be needed for patients with chronic hypertension (consider raising no higher than 40 mmHg below pre-existing systolic pressure) 3
• Can be initiated during fluid resuscitation if hypotension is severe enough to risk cerebral or coronary ischemia 3

Cardiogenic Shock (Conditional Use)

• Use norepinephrine in persistently hypotensive cardiogenic shock with tachycardia 2
• Avoid in bradycardic cardiogenic shock (consider dopamine instead) 2
• Balance MAP goals against negative impacts on cardiac output and myocardial oxygen consumption 2

Other Shock States

• Cardiac arrest: Used to maintain systemic blood pressure during resuscitation after effective heartbeat and ventilation are established 3
• Anaphylaxis: Can be used when epinephrine alone is insufficient

Dosing Protocol

Preparation and Administration

• Dilution: Must be diluted in 5% dextrose or 5% dextrose with saline (NOT saline alone due to oxidation risk) 3
• Standard concentration: 4 mg in 1000 mL = 4 mcg/mL 3
• Route: Administer via large central vein when possible, though peripheral administration can be safe with appropriate protocols 4
• Monitoring: Arterial line placement recommended for all patients requiring vasopressors 1

Initial Dosing

• Starting dose: 8-12 mcg/min (2-3 mL/min of standard dilution), equivalent to approximately 0.05-0.1 mcg/kg/min 3
• Recent evidence suggests higher initial doses (0.1 mcg/kg/min) achieve target MAP faster and may improve outcomes, particularly when baseline MAP <50 mmHg 5
• Weight-based considerations: Obese patients require lower weight-based doses but similar absolute doses compared to non-obese patients 6

Maintenance Dosing

• Average maintenance: 2-4 mcg/min (0.5-1 mL/min), equivalent to 0.01-0.03 mcg/kg/min 3
• Titration: Dose to effect based on MAP and perfusion markers (lactate clearance, urine output, mental status, skin perfusion) 2, 1
• High-dose threshold: Doses ≥1 mcg/kg/min are considered high; at this point, consider adding second-line agents 7
• Maximum reported: Up to 68 mg/day (17 vials) in refractory cases, though occult hypovolemia should always be suspected at high doses 3

Second-Line Agents (When Norepinephrine Insufficient)

• Vasopressin: Add up to 0.03 units/min to raise MAP or decrease norepinephrine requirements 1
• Epinephrine: Add when additional agent needed or use as single agent 1
• Dobutamine: Add if evidence of myocardial dysfunction with persistent hypoperfusion despite adequate MAP 1

Absolute Contraindications

Volume Depletion

Critical caveat: Norepinephrine should NOT be used as monotherapy in hypovolemic shock except as a temporary emergency measure to maintain coronary/cerebral perfusion until volume replacement is completed 3

• Continuous use without volume replacement causes: severe peripheral vasoconstriction, decreased renal perfusion, poor systemic flow despite "normal" BP, tissue hypoxia, and lactic acidosis 3

Mesenteric/Peripheral Vascular Thrombosis

• Contraindicated due to risk of extending ischemia and infarction area 3
• Exception: May be used as life-saving measure if attending physician deems necessary 3

Anesthetic Interactions

• Cyclopropane and halothane anesthesia: Generally contraindicated due to risk of ventricular tachycardia/fibrillation from increased cardiac irritability 3
• Profound hypoxia or hypercarbia: Same arrhythmia risk applies 3

Monitoring and Safety

Essential Monitoring

• Continuous arterial pressure monitoring via arterial line 1
• Central venous pressure: Helpful for detecting occult hypovolemia, especially at high doses 3
• Perfusion markers: Serial lactate, urine output, mental status, skin perfusion, organ function tests 2
• Cardiac output monitoring: Desired when available, as vasopressors impact cardiac function 2

Peripheral Administration Considerations

• Can safely avoid central line placement in 51.6% of patients using appropriate protocols 4
• Extravasation rate: 75.8 events/1000 catheter-days, but most cause minimal injury with no surgical interventions required 4
• Use large peripheral vein, secure catheter well, monitor site closely 3

Weaning Strategy

• Reduce gradually; avoid abrupt withdrawal 3
• Continue until adequate BP and tissue perfusion maintained without therapy 3
• Treatment duration varies widely (up to 6 days reported in myocardial infarction cases) 3

Clinical Pearls and Pitfalls

Common pitfall: Failing to achieve MAP ≥65 mmHg within 60 minutes is independently associated with increased ICU mortality (OR 1.49) 5. If initial dose inadequate, uptitrate promptly rather than waiting.

Timing matters: Prehospital norepinephrine administration to achieve MAP >65 mmHg is associated with reduced 30-day mortality in septic shock (HR 0.42) 8, supporting early aggressive treatment.

Dose-related kidney injury: Both intraoperative hypotension AND cumulative norepinephrine dose are independently associated with postoperative AKI 9. Avoid both profound hypotension and unnecessarily high norepinephrine doses.

Visual inspection: Do not use if solution is pinkish, darker than slightly yellow, or contains precipitate 3

Drug interactions: Avoid contact with iron salts, alkalis, or oxidizing agents 3